Exact Sciences Set To Dominate Emerging Precision Oncology Market: Analyst Applauds $18B Potential Market
Portfolio Pulse from Nabaparna Bhattacharya
Exact Sciences Corporation (NASDAQ:EXAS) is poised to dominate the emerging precision oncology market, with a potential $18 billion market. Analysts reiterate Buy ratings and raise price targets, as the company's Cologuard test shows promising results and management remains confident in future growth prospects.
June 22, 2023 | 6:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exact Sciences is set to dominate the emerging precision oncology market with its Cologuard test, which addresses an $18 billion potential market. Analysts reiterate Buy ratings and raise price targets.
The article highlights Exact Sciences' potential to dominate the emerging precision oncology market with its Cologuard test, which has demonstrated 94% sensitivity for colorectal cancer at 91% specificity. Analysts have reiterated Buy ratings and raised price targets, indicating a positive outlook for the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 100
RELEVANCE 100